MSD Korea will supply the hepatitis C treatment Zepatier in Korean market
MSD Korea(CEO Avi BenShoshan) announced the launch of its own chronic hepatitis C treatment Zepatier™ (generic name: elbasvir/grazoprevir) on the 16th.
With the launch, Zepatier, a drug for the treatment of genotype 1a and 1b patients with or without ribavirin(RBV), now can be used as the 12-wee...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
